<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Allogeneic stem cell transplantation (allo-SCT) is the only treatment with curative potential for patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>From June 1986 to April 1997, we treated 12 patients with primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (5 men, 7 women, median age, 36.5 years) by allo-SCT </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients had one or more of the following poor prognostic factors: intermediate-2 or high-risk categories according to the International Prognostic Scoring System; disease progression during follow-up; heavy transfusion requirements and <z:hpo ids='HP_0002719'>recurrent infections</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>The median duration from diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> to allo-SCT was 6 months </plain></SENT>
<SENT sid="4" pm="."><plain>The preconditioning regimen included total body irradiation combined with either high-dose <z:chebi fb="0" ids="28680">cytarabine</z:chebi> (n = 6), high-dose <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (n = 4), or other regimens (n = 2) </plain></SENT>
<SENT sid="5" pm="."><plain>Ten patients received bone marrow transplantations and two patients received peripheral blood stem cell transplantations </plain></SENT>
<SENT sid="6" pm="."><plain>Prophylaxis for <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD) consisted of standard cyclosporin and short-course <z:chebi fb="0" ids="44185">methotrexate</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> GVHD of grade 2 or above occurred in 10 patients, while <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD occurred in seven of the nine patients who survived longer than 6 months after allo-SCT </plain></SENT>
<SENT sid="8" pm="."><plain>With a median follow-up of 50 months, <z:hpo ids='HP_0000001'>all</z:hpo> nine patients with human leukocyte antigen (HLA)-matched sibling donors survived </plain></SENT>
<SENT sid="9" pm="."><plain>One patient had a relapse 6 months after transplantation and achieved complete remission again with low-dose <z:chebi fb="0" ids="28680">cytarabine</z:chebi> therapy </plain></SENT>
<SENT sid="10" pm="."><plain>The three patients receiving allo-SCT from unrelated or HLA-mismatched donors died of grade 3 to 4 <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD and <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> within 5 months after transplantation </plain></SENT>
<SENT sid="11" pm="."><plain>The estimated disease-free survival at 4 years was 67% (95% confidence interval, 40-93%), and the overall survival was 75% (95% confidence interval, 50-99%) </plain></SENT>
<SENT sid="12" pm="."><plain>Our data suggest that allo-SCT should be considered early in the clinical course for young <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients with a poor prognosis and a matched sibling donor </plain></SENT>
</text></document>